1. Home
  2. KF vs MDXH Comparison

KF vs MDXH Comparison

Compare KF & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korea Fund Inc. (The) New

KF

Korea Fund Inc. (The) New

HOLD

Current Price

$49.60

Market Cap

197.9M

Sector

Finance

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.42

Market Cap

183.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KF
MDXH
Founded
1984
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
197.9M
183.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
KF
MDXH
Price
$49.60
$3.42
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
18.4K
123.5K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
N/A
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.68
52 Week Low
$18.30
$1.35
52 Week High
$25.56
$5.33

Technical Indicators

Market Signals
Indicator
KF
MDXH
Relative Strength Index (RSI) 72.46 44.64
Support Level $45.21 $3.45
Resistance Level $49.89 $3.80
Average True Range (ATR) 1.46 0.20
MACD -0.00 -0.02
Stochastic Oscillator 69.21 5.00

Price Performance

Historical Comparison
KF
MDXH

About KF Korea Fund Inc. (The) New

Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and Others.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: